Treating autoimmune and inflammatory diseases with enhanced regulatory T-cells [electronic resource] / David Klatzmann.
Material type:
FilmPublisher number: 11002 | Henry Stewart TalksSeries: Henry Stewart talks. Biomedical & life sciences collection.Publication details: London : Henry Stewart Talks, 2022.Description: 1 online resource (1 streaming video file (54 min.) : color, sound)Subject(s): - Autoimmune diseases -- Treatment
- Inflammation -- Treatment
- Interleukin-2 -- Therapeutic use
- T cells -- Therapeutic use
- Adoptive Transfer
- Autoimmune Diseases -- drug therapy
- Autoimmune Diseases -- Immunology
- Cell- and Tissue-Based Therapy
- CTLA-4 Antigen
- Forkhead Transcription Factors
- Graft vs Host Disease -- immunology
- Immunotherapy -- methods
- Infections -- immunology
- Interleukin-2 -- therapeutic use
- Liver
- Lung
- Spleen
- T-Lymphocytes, Regulatory -- therapeutic use
Title from title frames.
Webinar.
Access restricted to subscribers.
Interleukin-2 (IL-2) is the main cytokine supporting regulatory T-cells (Tregs) development, survival and suppressive activity. However, Tregs cannot produce IL-2 and fully depend on exogenous IL-2. Treg cell therapy products are grown for weeks in culture medium containing IL-2 concentration that are 10 000-fold higher than the IL-2 serum concentration in humans. This generates "IL-2 addicted" Tregs that might not survive well and/or function optimally when reinjected in patients. We reasoned that Tregs that could produce their own IL-2 would have markedly improved therapeutic potential. ... Altogether, we believe that Treg cell products should be supported by IL-2 after injection to patients. This could be done by injecting low-dose IL-2 or advantageously by an autocrine production of IL-2 that dramatically improves the therapeutic potential of Tregs. This approach could be introduced in any form of Treg cell therapy, from polyclonal Tregs to antigen specific or targeted Tregs.
Mode of access: World Wide Web.
There are no comments on this title.